Investigating biomarkers for sepsis severity and mortality prediction
Study on the Mechanism of Endotoxic Acute Lung Injury-induced Golgi Stress Based on Regulating HO-1/CREB3
This study is trying to find specific markers in the blood that can help doctors understand how severe sepsis is and predict if patients will survive for 30 days.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Tianjin Nankai Hospital Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06045780 on ClinicalTrials.gov |
What this trial studies
This observational cohort study focuses on patients diagnosed with sepsis in the Intensive Care Unit of Nankai Hospital. It aims to identify valuable biomarkers that indicate the severity of sepsis and predict 30-day mortality rates. All participants must meet the Sepsis-3 criteria and provide informed consent. The study does not involve any interventions but relies on observational data to draw conclusions about sepsis management.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have been diagnosed with sepsis within the last 48 hours.
Not a fit: Patients who are pregnant, have certain cancers, or are participating in other intervention trials may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of high-risk sepsis patients and better management strategies.
How similar studies have performed: While there have been studies investigating biomarkers in sepsis, this specific approach focusing on HO-1/CREB3 modulation is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Males or females over the age of 18; 2. Sepsis was diagnosed within 48h which meets SPESIS 3 criteria; 3. Capable of understanding the purpose and risk of the study; 4. Patients or proxy must give written informed consent before any assessment is performed. Exclusion Criteria: 1. Pregnancy, lactation or perinatal period; 2. Breast carcinoma; 3. HIV seropositive or Syphilis seropositive; 4. Any clinical-relevant condition that might affect study participation and/or study results; 5. Participation in any other intervention trial; 6. Unwillingness or inability to following the study protocol in the investigators opinion.
Where this trial is running
Tianjin, Tianjin Municipality
- Tianjin Nankai Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jianbo Yu, MD
- Email: 30717008@nankai.edu.cn
- Phone: +8615344422323
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.